The ‘missed disease’ that affects 190 million: endometriosis drug shows early promise

A promising new treatment for endometriosis, a painful condition affecting around 190 million people, is being explored. Endometriosis occurs when uterine cells grow outside the uterus, causing lesions that are typically treated with surgery or hormone therapy, both of which have significant drawbacks. Researchers have modified niclosamide, a drug for parasitic infections, to target the disease’s cells and tested it in mice, showing potential for a non-surgical, non-hormonal treatment. Current treatments are inadequate, with many experiencing recurrence after surgery and hormone therapies causing disruptive side effects. Niclosamide’s low solubility poses a challenge, requiring high doses that lead to side effects, but if these issues are resolved, it could revolutionize treatment. QUESTION: How might the development of a non-surgical, non-hormonal treatment for endometriosis change the lives of those affected by the condition?